Toxicity testing on a new PET ligand for the NIH
ID: RFQ-CC-25-002889Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Testing Laboratories and Services (541380)

PSC

MEDICAL- LABORATORY TESTING (Q301)

Original Source

https://sam.gov/opp/1e16b1c3d52a43edbc2df8b066ae0938/view
Timeline
  1. 1
    Posted Mar 28, 2025, 12:00 AM UTC
  2. 2
    Updated Mar 28, 2025, 12:00 AM UTC
  3. 3
    Due Apr 4, 2025, 7:00 PM UTC
Description

The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a toxicity testing service on a new PET ligand, Fluorine-18-Fluorocellobiose, as part of the requirements for an Investigational New Drug (IND) application to the FDA. The project entails conducting a single-dose toxicity study in Sprague Dawley rats to assess potential toxic effects, establish the maximum tolerated dose (MTD), and determine the no observable adverse effect level (NOAEL), all under Good Laboratory Practice (GLP) conditions. This initiative is crucial for advancing biomedical research and improving imaging techniques in the diagnosis and treatment of infectious diseases. Interested parties must submit their proposals by April 4, 2025, with the contract period expected to last for one year, and inquiries can be directed to Lu Chang at lu-chang.lu@nih.gov.

Point(s) of Contact
Lu Chang
lu-chang.lu@nih.gov
Files
Title
Posted
STATEMENT-OF-WORK-fluorocellobiose 12 28 2024.docx
Mar 29, 2025, 1:04 AM UTC
The National Institutes of Health (NIH) seeks to contract a service for toxicity testing of a new PET ligand, Fluorine-18-Fluorocellobiose, required for an Investigational New Drug (IND) application to the FDA. The project involves a single-dose toxicity study in Sprague Dawley rats to determine the ligand's potential toxic effects and to establish maximum tolerated dose (MTD) and no observable adverse effect level (NOAEL). Testing will be conducted under Good Laboratory Practice (GLP) conditions, encompassing clinical observations, pathology evaluations, and detailed reporting of findings. Deliverables include comprehensive reports and datasets necessary for FDA submission, with a completion timeframe of up to 12 months post-authorization and receipt of study materials. There will be no government-furnished property needed, nor specific security requirements associated with the contract. This initiative underlines NIH's role in advancing biomedical research, particularly in the field of infectious diseases through improved imaging techniques. Efforts aim to validate the proposed human doses for the ligand, which could enhance diagnosis and treatment in related clinical applications.
Lifecycle
Title
Type
Toxicity testing on a new PET ligand for the NIH
Currently viewing
Combined Synopsis/Solicitation
Similar Opportunities
PATIENT SAFETY MONITORING IN INTERNATIONAL LABORATORIES (pSMILE)
Buyer not available
The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking qualified small businesses for a contract related to Patient Safety Monitoring in International Laboratories (pSMILE). The objective of this procurement is to enhance the capabilities of non-U.S. laboratories in conducting clinical trials in accordance with good clinical laboratory practices (GCLP), ensuring reliable test results and compliance with regulatory standards. The anticipated contract will support approximately 150 labs across 18 countries and includes key activities such as auditing lab compliance, supporting method validations, training laboratory staff, and managing a secure electronic repository for lab documentation. Interested organizations must submit detailed capability statements to demonstrate their expertise and relevant experience, with the contract expected to last for one base year and include six one-year options, potentially extending to a total of seven years. For further inquiries, contact Patrick Finn at patrick.finn@nih.gov or Robert Corno at cornorj@niaid.nih.gov.
Drug Manufacturing and Formulation Contract II
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified contractors for the Drug Manufacturing and Formulation Contract II (DFMC II) to support the manufacturing and documentation processes for investigational drug products. The primary objective of this procurement is to develop dosage forms of small molecule drug candidates for clinical trials and preclinical studies, ensuring compliance with Good Manufacturing Practices (cGMP) and regulatory standards set by the FDA and other governing bodies. This initiative is crucial for maintaining high standards in drug development and research support, facilitating the safe and effective delivery of investigational products. Interested parties should contact Dr. William H. M. Etti at William.Etti@nih.gov or call 301-402-4422 for further information regarding this opportunity, which includes a partial small business set-aside and is expected to be awarded under an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract framework.
Purchase of FY25 Nanion Consumables
Buyer not available
The U.S. Food and Drug Administration (FDA) is seeking quotations for the purchase of Nanion consumables to support ion channel pharmacology experiments using the SyncroPatch 384 automated patch clamp system. This procurement aims to facilitate research on drug effects on ion channels, which is crucial for understanding drug safety and efficacy, with a contract duration of 12 months and the possibility of a 12-month extension. The selected contractor will be responsible for delivering consumables in four separate batches throughout the year, ensuring compliance with federal contracting regulations. Interested parties should direct their inquiries to Freshta Javid or L. Maria Finan by April 17, 2025, at 12:00 PM ET, and must adhere to the total small business set-aside requirements under NAICS code 334516.
IDIQ for the purchase of human induced pluripotent stem cell-derived cells
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking to award a sole-source contract for the procurement of human induced pluripotent stem cell-derived cells from Fujifilm Cellular Dynamics. This acquisition aims to support a research program focused on microphysiological systems (MPS), which are critical for advanced in-vitro models used in drug safety and efficacy assessments. The cells, including cardiomyocytes, neurons, astrocytes, and hepatocytes, will be cryopreserved and utilized by FDA scientists at the Center for Drug Evaluation and Research, ensuring continuity in ongoing projects due to the established partnership with Fujifilm. Interested vendors may submit capability statements within 15 days of the notice, with the response deadline set for 10 AM EST on May 2, 2025; inquiries should be directed to Telisha Wilson at telisha.wilson@fda.hhs.gov.
Dissolved Non-Condensable Gas Testing
Buyer not available
The Department of Energy, through the Naval Nuclear Laboratory, is soliciting proposals for a project focused on "Dissolved Non-Condensable Gas Testing." This initiative aims to conduct experiments that quantify the behavior of non-condensable gases (NCGs) such as nitrogen, hydrogen, and oxygen in water during various processes, including diffusion across steam/water interfaces, condensation, boiling, and flashing under different temperature and pressure conditions. The research is critical for advancing nuclear technology and improving operational efficiencies, with proposals due by April 8, 2025. Interested suppliers must submit a one-page Quad Chart and a five-page narrative detailing their project approach, along with adherence to disclosure protocols for sensitive information. For further inquiries, contact ATIP at ATIP@unnpp.gov.
Q--T-Cell Manufacturing for Protocol 18-H-0012
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking contractors for T-Cell Manufacturing related to Protocol 18-H-0012. This procurement aims to fulfill the requirements for biological product manufacturing, which is crucial for advancing medical research and therapeutic applications. The contract falls under the NAICS code 325414, focusing on biological product manufacturing, and is categorized under medical laboratory testing services. Interested parties can reach out to Noelle Decenzo at noelle.decenzo@nih.gov or call +1 301 402 5571 for further details regarding this presolicitation opportunity.
RRPV Solicitation Summary: Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services
Buyer not available
The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking proposals for the establishment of a Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory. This initiative aims to enhance national health security by facilitating the rapid development of vaccines in response to potential pandemics, with a focus on conducting immunoassays to support vaccine research and clinical trials. The successful offeror will play a critical role in strengthening biodefense infrastructure by providing standardized laboratory services, with proposals due by May 30, 2025, and questions accepted until April 24, 2025. Interested parties can contact Rebecca Harmon at rebecca.harmon@ati.org for further information.
“Brand Name or Equal” Emulate Inc., Chip-R1 Rigid Chips, plus Preventive Maintenance and Repair Service on Emulate Modules
Buyer not available
The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified vendors to provide "Brand Name or Equal" Emulate Inc., Chip-R1 Rigid Chips, along with preventive maintenance and repair services for Emulate Modules. The procurement aims to support the National Center for Toxicological Research (NCTR) in evaluating a novel brain-chip system designed to assess neurotoxicity induced by CD19 CAR T-cells, which is critical for advancing research in neurotoxicology. Interested small businesses and other vendors capable of meeting the specified technical requirements are encouraged to submit capability statements by April 28, 2025, at 1:00 PM Central Time, to Warren Dutter at warren.dutter@fda.hhs.gov. This sources sought announcement does not constitute a solicitation for proposals, and no contract will be awarded from this announcement.
Pharmacogenomics (PGx) Testing for Military Readiness Pilot
Buyer not available
The Department of Defense, through the Defense Health Agency (DHA), is seeking proposals for a pilot program focused on pharmacogenomics (PGx) testing to enhance military readiness and healthcare delivery for Active-Duty service members. The initiative aims to establish standardized processes for routine PGx testing within the Military Health System (MHS), leveraging electronic health record (EHR) data to improve clinical decision-making and treatment outcomes. This program is critical for optimizing medication safety and efficacy, ultimately preventing adverse drug reactions and improving overall health conditions for military personnel. Interested parties should contact Dr. Lauren Palestrini at lauren.palestrini@mtec-sc.org, with a funding availability of $2.2 million and a project duration of up to 36 months. The Request for Project Proposals (RPP) is expected to be released soon, with a proposal preparation period of approximately 30 days.
Bio Threat Detection Instrument
Buyer not available
The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Safeware, Inc. for the procurement of a BioMeMe Bio Threat Detection Instrument. This new instrument is required to enhance the NIH Division of Fire and Rescue Services' capabilities by allowing simultaneous screening for 14 biological agents, replacing the outdated RAZOR Biothreat detection system that will soon be unsupported. The acquisition is critical for maintaining the NIH's FEMA Type I Hazardous Materials Unit designation and ensuring the safety of employees and visitors during biological research activities. Interested parties that believe they can fulfill the requirements must submit a capability statement by 9:00 AM (Eastern Time) on May 2, 2025, to the primary contact, Van V. Holley, at holleyv@od.nih.gov.